Both IL‐12 and IL‐18 contribute to small intestinal Th1‐type immunopathology following oral infection with Toxoplasma gondii, but IL‐12 is dominant over IL‐18 in parasite control
Open Access
- 15 September 2004
- journal article
- host defense
- Published by Wiley in European Journal of Immunology
- Vol. 34 (11) , 3197-3207
- https://doi.org/10.1002/eji.200424993
Abstract
Oral infection of C57BL/6 mice with Toxoplasma gondii results in small intestinal Th1‐type immunopathology mediated by local production of IFN‐γ, TNF‐α, and NO. To analyze whether the proinflammatory cytokines IL‐12 and IL‐18 play a role in the induction of immunopathology, IL‐12p35/p40–/– and IL‐18–/– mice were orally infected with T. gondii. Wild‐type mice developed massive necrosis in their small intestines and died 7–10 days post infection. Even though IL‐12p35/40–/– mice did not develop the necrosis they all died between day 9 and 11 after infection. In contrast, 50% of IL‐18–/– mice died during the acute phase of infection. Compared to wild‐type mice, IL‐12p35/p40–/– but not IL‐18–/– mice showed significantly higher parasite numbers in their small intestines and significantly higher numbers of parasite‐associated inflammatory foci in their livers. IFN‐γ production was similar in infected wild‐type and IL‐18–/– mice but significantly decreased in IL‐12p35/p40–/– mice. Treatment of mice with anti‐IL‐12‐ or anti‐IL‐18 antibodies after infection prevented the development of intestinal necrosis. These results reveal that both IL‐12 and IL‐18 play an important role in the development of intestinal immunopathology following oral infection with T. gondii. However, IL‐12 is dominant over IL‐18 in the host defense against parasite replication. Therefore, neutralization of IL‐18 (rather than TNF‐α, IL‐12, and IFN‐γ) may be a safe strategy for the treatment of Th1‐associated diseases.Keywords
This publication has 46 references indexed in Scilit:
- Interleukin‐18 and Host Defense against InfectionThe Journal of Infectious Diseases, 2003
- Role of Interleukin-18 in Host Defense against DisseminatedCandida albicansInfectionInfection and Immunity, 2002
- Anti-Interleukin-18 Therapy in Murine Models of Inflammatory Bowel DiseasePathobiology, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Interleukin-18 Regulates Both Th1 and Th2 ResponsesAnnual Review of Immunology, 2001
- Role of Interleukin-18 (IL-18) during Lethal Shock: Decreased Lipopolysaccharide Sensitivity but Normal Superantigen Reaction in IL-18-Deficient MiceInfection and Immunity, 2000
- IN VIVO ANTIVIRAL EFFECT OF INTERLEUKIN 18 IN A MOUSE MODEL OF VACCINIA VIRUS INFECTIONCytokine, 1999
- Defective NK Cell Activity and Th1 Response in IL-18–Deficient MiceImmunity, 1998
- IGIF Does Not Drive Th1 Development but Synergizes with IL-12 for Interferon-γ Production and Activates IRAK and NFκBImmunity, 1997
- Cloning of a new cytokine that induces IFN-γ production by T cellsNature, 1995